Cargando…

FARMAPRICE: A Pharmacogenetic Clinical Decision Support System for Precise and Cost-Effective Therapy

Pharmacogenetic (PGx) guidelines for the precise dosing and selection of drugs remain poorly implemented in current clinical practice. Among the barriers to the implementation process is the lack of clinical decision support system (CDSS) tools to aid health providers in managing PGx information in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roncato, Rossana, Dal Cin, Lisa, Mezzalira, Silvia, Comello, Francesco, De Mattia, Elena, Bignucolo, Alessia, Giollo, Lorenzo, D’Errico, Simone, Gulotta, Antonio, Emili, Luca, Carbone, Vincenzo, Guardascione, Michela, Foltran, Luisa, Toffoli, Giuseppe, Cecchin, Erika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523070/ https://www.ncbi.nlm.nih.gov/pubmed/30987397 http://dx.doi.org/10.3390/genes10040276

Ejemplares similares

Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma
por: De Mattia, Elena, et al.
Publicado: (2019)

Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment
por: Bignucolo, Alessia, et al.
Publicado: (2017)

Pharmacogenetics Role of Genetic Variants in Immune-Related Factors: A Systematic Review Focusing on mCRC
por: Scarabel, Lucia, et al.
Publicado: (2022)

The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines
por: De Mattia, Elena, et al.
Publicado: (2019)

Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: Lessons learned on the path to implementation
por: Bignucolo, A., et al.
Publicado: (2023)

Circulating-Free DNA Analysis in Hepatocellular Carcinoma: A Promising Strategy to Improve Patients’ Management and Therapy Outcomes
por: Mezzalira, Silvia, et al.
Publicado: (2019)

Sex Disparities in Efficacy in COVID-19 Vaccines: A Systematic Review and Meta-Analysis
por: Bignucolo, Alessia, et al.
Publicado: (2021)

Germline Polymorphisms in the Nuclear Receptors PXR and VDR as Novel Prognostic Markers in Metastatic Colorectal Cancer Patients Treated With FOLFIRI
por: De Mattia, Elena, et al.
Publicado: (2019)

Genetic biomarkers for hepatocellular cancer risk in a caucasian population
por: De Mattia, Elena, et al.
Publicado: (2017)

SMAD3 Host and Tumor Profiling to Identify Locally Advanced Rectal Cancer Patients at High Risk of Poor Response to Neoadjuvant Chemoradiotherapy
por: De Mattia, Elena, et al.
Publicado: (2021)

Impact of ABCG2 and ABCB1 Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-Analysis
por: Dalle Fratte, Chiara, et al.
Publicado: (2023)

Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy
por: De Mattia, Elena, et al.
Publicado: (2020)

The use of therapeutic drug monitoring to highlight an over-looked drug-drug interaction leading to imatinib treatment failure
por: Gagno, Sara, et al.
Publicado: (2023)

NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome
por: Michelotti, Anna, et al.
Publicado: (2021)

IL15RA and SMAD3 Genetic Variants Predict Overall Survival in Metastatic Colorectal Cancer Patients Treated with FOLFIRI Therapy: A New Paradigm
por: De Mattia, Elena, et al.
Publicado: (2021)

Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients
por: De Mattia, Elena, et al.
Publicado: (2018)

LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring
por: Canil, Giovanni, et al.
Publicado: (2023)

Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk
por: De Mattia, Elena, et al.
Publicado: (2022)

Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19
por: Scarabel, Lucia, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma
por: Guardascione, Michela, et al.
Publicado: (2020)

CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions
por: Roncato, Rossana, et al.
Publicado: (2020)

The burden of rare variants in DPYS gene is a novel predictor of the risk of developing severe fluoropyrimidine-related toxicity
por: De Mattia, Elena, et al.
Publicado: (2023)

Predictive and Prognostic Value of Oncogene Mutations and Microsatellite Instability in Locally-Advanced Rectal Cancer Treated with Neoadjuvant Radiation-Based Therapy: A Systematic Review and Meta-Analysis
por: De Mattia, Elena, et al.
Publicado: (2023)

New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach
por: Garziera, Marica, et al.
Publicado: (2019)

Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC)
por: Garziera, Marica, et al.
Publicado: (2019)

Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients
por: Dreussi, Eva, et al.
Publicado: (2016)

JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future
por: Angelini, Jacopo, et al.
Publicado: (2020)

A rapid, simple and sensitive LC-MS/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoring
por: Zanchetta, Martina, et al.
Publicado: (2021)

Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS)
por: Garziera, Marica, et al.
Publicado: (2018)

Resveratrol in Cancer Patients: From Bench to Bedside
por: Berretta, Massimiliano, et al.
Publicado: (2020)

Clonal Selection of a Novel Deleterious TP53 Somatic Mutation Discovered in ctDNA of a KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumor Resistant to Imatinib
por: Dalle Fratte, Chiara, et al.
Publicado: (2020)

An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer
por: Roncato, Rossana, et al.
Publicado: (2022)

A Panel of Tumor Biomarkers to Predict Complete Pathological Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer
por: Dalle Fratte, Chiara, et al.
Publicado: (2022)

A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy
por: De Mattia, Elena, et al.
Publicado: (2018)

Pharmacogenetics of FSH Action in the Female
por: Conforti, Alessandro, et al.
Publicado: (2019)

Editorial: Precision psychiatry from a pharmacogenetics perspective
por: Brown, Lisa C., et al.
Publicado: (2023)

Cancer pharmacogenetics
por: Marsh, S, et al.
Publicado: (2004)

Experimental Pharmacogenetics
por: Lubs, Herbert A.
Publicado: (1964)

Pharmacogenetics of Anticoagulants
por: Rane, Anders, et al.
Publicado: (2010)

Pharmacogenetics of osteoporosis
por: Marini, Francesca, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_1ukdq4ldpcula77uul33kt93ol